A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients With Type 2 Diabetes Within Blood Glucose Target Ranges

Date: 
April, 2017
March 2017. This analysis assessed glycemic fluctuations and day-to-day blood glucose variability in patients treated with IDegLira compared with either insulin degludec (IDeg) or liraglutide alone. Investigators analyzed data from 2 randomized trials in patients with type 2 diabetes (T2D); in particular, 9-point self-monitored blood glucose (SMBG) profiles and continuous glucose monitoring (CGM) data from a patient subset. Patients treated with IDegLira were more likely to have SMBG values in target ranges for pre- and postprandial values and for the full 9-point profile (P